Adlai Nortye Group Ltd. (NasdaqGM: ANL)
Health Care · Biotechnology · SG
$15.62
+3.51% today · +877.7% 1Y
Adlai Nortye Group Ltd. (NasdaqGM: ANL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.01B and employs 109 people.
Over the last twelve months the share price has gained 877.7%, trading between 0.88 and 17.25.
Tweenvest scores Adlai Nortye Group Ltd. across four factors: quality 36/100, value 70/100. Its strongest factor is value.
ANL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.01B
- Revenue (TTM)
- $18.06M
- P/E
- —
- EPS
- -0.56
- Dividend yield
- —
- Beta (5Y)
- 1.11
- 52-week high
- $17.25
- 52-week low
- $0.88
- Avg volume (3M)
- —
- Shares outstanding
- 64.40M
- Employees
- 109
- Next earnings
- —
About Adlai Nortye Group Ltd.
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
- ISIN
- US00704R1095
- Founded
- 2004
- Listed since
- Sep 29, 2023
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| MeiraGTx Holdings plcNasdaqGS: MGTX | $1.03B | $10.69 | -0.93% |
| Immatics N.V.NasdaqCM: IMTX | $1.02B | $7.43 | -2.11% |
| Kolon TissueGene, Inc.KOSDAQ: A950160 | $1.01B | ₩16,030.00 | -0.62% |
| Aktis Oncology, Inc.NasdaqGS: AKTS | $1.01B | $18.15 | +2.31% |
| Cullinan Therapeutics, Inc.NasdaqGS: CGEM | $999.43M | $15.53 | +0.45% |
| Philogen S.p.A.BIT: PHIL | $991.45M | €22.00 | +0.69% |
| Jiangsu Aidea Pharmaceutical Group Co., Ltd.SHSE: 688488 | $989.43M | CN¥15.75 | -5.29% |
| Basilea Pharmaceutica AGSWX: BSLN | $979.21M | CHF65.50 | -1.95% |
Figures last refreshed Oct 11, 2026.